Deutsche Bank raising its price target on Eli Lilly to $1,025 from $725, calling it a “low beta and high growth unicorn.” Analyst James Shin joined CNBC Overtime to discuss his call.

Make a post in our subreddit XGramatikInsights, and your thoughts will appear here!

Share the Post:

Related Posts